OA03.04 A Phase 1b Study of Furmonertinib, an Oral, Brain Penetrant, Selective EGFR Inhibitor, in Patients with Advanced NSCLC with EGFR Exon 20 Insertions

Epidermal growth factor receptor (EGFR) Exon 20 insertion (Exon20ins) mutations constitute approximately 9% of all the EGFR mutations (Robichaux et al. 2021) in non-small cell lung cancer (NSCLC). Furmonertinib is an oral, brain penetrant, EGFR tyrosine kinase inhibitor (TKI) engineered for broad activity and selectivity across EGFR mutations including Exon20ins (Musib et al., NACLC 2022). Furmonertinib is being studied in an ongoing phase 1b clinical trial in NSCLC patients with EGFR Exon20ins mutations (FAVOUR; NCT04858958).